{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:20:42Z","timestamp":1790130042136,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40120-024-00595-9","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T14:02:54Z","timestamp":1711029774000},"page":"625-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-505X","authenticated-orcid":false,"given":"Marco","family":"Luigetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chao","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Aldinc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"595_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11897-013-0182-4","volume":"11","author":"M Hanna","year":"2014","unstructured":"Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014;11:50\u20137.","journal-title":"Curr Heart Fail Rep"},{"key":"595_CR2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","volume":"106","author":"D Mohty","year":"2013","unstructured":"Mohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106:528\u201340.","journal-title":"Arch Cardiovasc Dis"},{"key":"595_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","volume":"85","author":"D Adams","year":"2015","unstructured":"Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology. 2015;85:675\u201382.","journal-title":"Neurology"},{"key":"595_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","volume":"47","author":"PN Hawkins","year":"2015","unstructured":"Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47:625\u201338.","journal-title":"Ann Med"},{"key":"595_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0969-2126(97)00215-3","volume":"5","author":"JW Kelly","year":"1997","unstructured":"Kelly JW. Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure. 1997;5:595\u2013600.","journal-title":"Structure"},{"key":"595_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/biomedicines7010011","volume":"7","author":"H Koike","year":"2019","unstructured":"Koike H, Katsuno M. Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights. Biomedicines. 2019;7:11.","journal-title":"Biomedicines"},{"key":"595_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","volume":"8","author":"T Damy","year":"2015","unstructured":"Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015;8:117\u201327.","journal-title":"J Cardiovasc Transl Res"},{"key":"595_CR8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/msj.21352","volume":"79","author":"SC Shin","year":"2012","unstructured":"Shin SC, Robinson-Papp J. Amyloid neuropathies. Mt Sinai J Med. 2012;79:733\u201348.","journal-title":"Mt Sinai J Med"},{"key":"595_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o I, Gonzalez-Duarte A, Obici L, et al. \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21:5\u20139.","journal-title":"J Peripher Nerv Syst"},{"key":"595_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15:387\u2013404.","journal-title":"Nat Rev Neurol"},{"key":"595_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34:520\u20138.","journal-title":"Eur Heart J"},{"key":"595_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB. THAOS\u2014the Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29:63\u201376.","journal-title":"Curr Med Res Opin"},{"key":"595_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","volume":"27","author":"L Obici","year":"2020","unstructured":"Obici L, Berk JL, Gonz\u00e1lez-Duarte A, et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2020;27:153\u201362.","journal-title":"Amyloid"},{"key":"595_CR14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019884","author":"D Adams","year":"2023","unstructured":"Adams D, Algalarrondo V, Echaniz-Laguna A. Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide & CRISPR-Cas9 treatments. Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2023019884.","journal-title":"Blood"},{"key":"595_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","volume":"22","author":"PL Swiecicki","year":"2015","unstructured":"Swiecicki PL, Zhen DB, Mauermann ML, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015;22:123\u201331.","journal-title":"Amyloid"},{"key":"595_CR16","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","volume":"33","author":"PT Sattianayagam","year":"2012","unstructured":"Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33:1120\u20137.","journal-title":"Eur Heart J"},{"key":"595_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13023-020-1340-x","volume":"15","author":"M Ines","year":"2020","unstructured":"Ines M, Coelho T, Conceicao I, Ferreira L, de Carvalho M, Costa J. Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study. Orphanet J Rare Dis. 2020;15:67.","journal-title":"Orphanet J Rare Dis"},{"key":"595_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1750-1172-9-61","volume":"9","author":"J Wixner","year":"2014","unstructured":"Wixner J, Mundayat R, Karayal ON, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis\u2014common complications of a rare disease. Orphanet J Rare Dis. 2014;9:61.","journal-title":"Orphanet J Rare Dis"},{"key":"595_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11\u201321.","journal-title":"N Engl J Med"},{"key":"595_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22\u201331.","journal-title":"N Engl J Med"},{"key":"595_CR21","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658\u201367.","journal-title":"JAMA"},{"key":"595_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","volume":"267","author":"A Gonz\u00e1lez-Duarte","year":"2020","unstructured":"Gonz\u00e1lez-Duarte A, Berk JL, Quan D, et al. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J Neurol. 2020;267:703\u201312.","journal-title":"J Neurol"},{"key":"595_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785\u201392.","journal-title":"Neurology"},{"key":"595_CR24","unstructured":"Alnylam Pharmaceuticals Inc. US prescribing information: ONPATTRO (patisiran) lipid complex injection, for intravenous use. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210922s000lbl.pdf. Accessed Nov 8, 2023."},{"key":"595_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/13506129.2022.2118043","volume":"30","author":"D Quan","year":"2023","unstructured":"Quan D, Obici L, Berk JL, et al. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial. Amyloid. 2023;30:49\u201358.","journal-title":"Amyloid"},{"key":"595_CR26","unstructured":"Alnylam Pharmaceuticals Inc. US prescribing information: AMVUTTRA (vutrisiran) injection, for subcutaneous use: Food and Drug Administration. 2022. https:\/\/www.alnylam.com\/sites\/default\/files\/pdfs\/amvuttra-us-prescribing-information.pdf. Accessed Nov 8, 2023."},{"key":"595_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30:1\u20139.","journal-title":"Amyloid"},{"key":"595_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116424","volume":"405","author":"PJB Dyck","year":"2019","unstructured":"Dyck PJB, Gonz\u00e1lez-Duarte A, Obici L, et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS+7. J Neurol Sci. 2019;405: 116424.","journal-title":"J Neurol Sci"},{"key":"595_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jns5.12059","volume":"19","author":"EJ Vinik","year":"2014","unstructured":"Vinik EJ, Vinik AI, Paulson JF, et al. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2014;19:104\u201314.","journal-title":"J Peripher Nerv Syst"},{"key":"595_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","volume":"76","author":"SI van Nes","year":"2011","unstructured":"van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. 2011;76:337\u201345.","journal-title":"Neurology"},{"key":"595_CR31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/ene.13510","volume":"25","author":"BK Gundapaneni","year":"2017","unstructured":"Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2017;25:464\u20138.","journal-title":"Eur J Neurol"},{"key":"595_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13023-018-0947-7","volume":"13","author":"L Amass","year":"2018","unstructured":"Amass L, Li H, Gundapaneni BK, Schwartz JH, Keohane DJ. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet J Rare Dis. 2018;13:225.","journal-title":"Orphanet J Rare Dis"},{"key":"595_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126526","volume":"4","author":"C Monteiro","year":"2019","unstructured":"Monteiro C, Mesgazardeh JS, Anselmo J, et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. 2019;4: e126526.","journal-title":"JCI Insight"},{"key":"595_CR34","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1111\/ene.15325","volume":"29","author":"M Luigetti","year":"2022","unstructured":"Luigetti M, Antonini G, Di Paolantonio A, et al. Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy. Eur J Neurol. 2022;29:2148\u201355.","journal-title":"Eur J Neurol"},{"key":"595_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","volume":"29","author":"Y Ando","year":"2022","unstructured":"Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29:143\u201355.","journal-title":"Amyloid"},{"key":"595_CR36","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","volume":"268","author":"D Adams","year":"2021","unstructured":"Adams D, Ando Y, Beirao JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268:2109\u201322.","journal-title":"J Neurol"},{"key":"595_CR37","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y, et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation. 2022;146:1657\u201370.","journal-title":"Circulation"},{"key":"595_CR38","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. J Am Coll Cardiol. 2023;81:1076\u2013126.","journal-title":"J Am Coll Cardiol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00595-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00595-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00595-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T07:32:50Z","timestamp":1716967970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00595-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00595-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The HELIOS-A study (NCT03759379) was conducted in accordance with the International Conference of Harmonisation guidelines for Good Clinical Practice, local regulatory requirements, and the principles of the Declaration of Helsinki. The study was approved by Ethics Committees or Institutional Review Boards for each study site (listed in the Supplementary Material), and all patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Marco Luigetti reports consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Alnylam Pharmaceuticals, Pfizer, and Sobi. Dianna Quan reports research funding from Alnylam Pharmaceuticals, Avidity Biosciences, Cytokinetics, Ionis Pharmaceuticals, Janssen Pharmaceuticals (formerly Momenta Pharmaceuticals), Pfizer, and Viela Bio, and consulting fees from Alnylam Pharmaceuticals and Ionis Pharmaceuticals. John L. Berk reports research funding from Alnylam Pharmaceuticals, AstraZeneca, Eidos Therapeutics, and Ionis Pharmaceuticals, consulting fees from Alnylam Pharmaceuticals, AstraZeneca, Eidos Therapeutics, Intellia Therapeutics, and Ionis Pharmaceuticals, and data safety monitoring and\/or advisory board membership for Alnylam Pharmaceuticals, AstraZeneca, Corino Therapeutics, Intellia Therapeutics, and Ionis Pharmaceuticals. Isabel Concei\u00e7\u00e3o reports consulting fees from Alnylam Pharmaceuticals, AstraZeneca, Pfizer, and Sobi, payment or honoraria for lectures, presentations, speakers bureaus, or educational events from Akcea Therapeutics, Alnylam Pharmaceuticals, AstraZeneca, and Pfizer, and data safety monitoring and\/or advisory board membership for Akcea Therapeutics, Alnylam Pharmaceuticals, and Intellia Therapeutics. Yohei Misumi reports research funding and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Alnylam Pharmaceuticals and Pfizer. Chi-Chao Chao has nothing to disclose. Shaun Bender, Emre Aldinc, and John Vest are all employees of Alnylam Pharmaceuticals. Emre Aldinc and John Vest report ownership of equity in Alnylam Pharmaceuticals. David Adams reports consulting fees from Alnylam Pharmaceuticals and AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}